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Injections are one of the most common health care procedures. According to
WHO data, there are 16 billion medical injections performed annually in developing and
transitional countries. In countries where unnecessary injections are common, the average
number of injections per person has been estimated to be 3.7 per year and half of them
are estimated to be unsafe injections (Hauri AM et al., 2003).
Each year, reuse or unsafe practice of injection devices may cause 20 million
infections with hepatitis B virus (HBV), 2 million infections with hepatitis C virus
(HCV), and 250,000 infections with human immunodeficiency virus (HIV) worldwide.
Like many developing countries, unsafe injection practices are a significant issue for
Central Asian countries of Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and
Uzbekistan. In addition to unsafe injections, overuse of transfusions of blood and blood
products, reuse of single use medical equipment, inadequate sterilization, improper
disposal of sharps (e.g., needles, scalpel blades, etc.) are also major cause of concern in
Central Asia.
The term “injection safety” was initially used when it was recognized that
injections—which are typically thought of as being intramuscular—may be an important
mode of transmission of HIV or hepatitis viruses. More recently, the term has been
broadened to include other means of parenteral injection of substances (intravenously),
withdrawing of blood (phlebotomy) or for intravenous/intra-arterial access (catheters in
veins or arteries).
WHO’s definition of safe injections is: A safe injection, phlebotomy, lancet
procedure or intravenous device insertion does not harm the recipient, does not expose

2

the provider to any avoidable risk and does not result in any waste that is dangerous for
other people.”
The HIV epidemic in Central Asian Republics of Kazakhstan, Kyrgyzstan,
Tajikistan, Turkmenistan, and Uzbekistan is primarily driven by injecting drug users
(IDUs), however, Ministries of Health (MoHs) estimate that anywhere between 2-15% of
the HIV transmissions occur due to nosocomial infections. However, lack of proper
monitoring and evaluation systems in the region have led many to believe that a larger
proportion of HIV transmission is caused by nosocomial infection in Central Asia.
The first HIV outbreak in the region occurred in 2006 when more than 130
children were infected with HIV in Shymkent, Kazakhstan. Outbreak investigation
conducted by the Centers for Disease Control and Prevention (CDC) cited intravenous
route of medication, subclavian vein catherization, and use of blood or blood products as
the main risk factors for HIV transmission.
In early 2007, another HIV outbreak was reported in Osh, Kyrgyzstan, where
initially it was reported that at least 26 people, mostly children, acquired HIV infection in
two local hospitals. CDC was asked again to conduct an investigation and estimated that
the number of children infected exceeded 100. The results of the investigation cited
intramuscular and intravenous injections to be the primary risk factor for HIV
transmission as well. Data from the CDC outbreak investigation is presented below.
Also in 2007, HIV outbreak was reported in Andijan, Uzbekistan among 7
children; however, the government never confirmed the outbreak. Although no evidence
exists it is believed that nosocomial infection was the primary cause of the outbreak.
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Subsequently, in November 2008, BBC reported that more than 40 children were
infected with HIV in Namangan, Uzbekistan. Uzbek government did not request CDC to
investigate the outbreak, however, a team of UN agencies, including UNAIDS, UNICEF,
and WHO, visited Namangan on a fact finding mission. UN agencies reported unsafe
injection practices to be the primary risk factor for HIV transmission among children.
Then, in March 2010, an Uzbek documentary was leaked to the media that claimed more
than 147 children were infected with HIV between 2007 and 2008 in Namangan alone.
After each of the outbreak that CDC investigated, CDC provided training to
physicians and healthcare workers on proper injecting techniques, however, it was
evident that localized trainings or interventions would not prevent HIV outbreaks
elsewhere in the region. Thus, CDC and Central Asia AIDS Project (CAAP), a regional
entity, started to exchange ideas on how best to provide assistance to MoHs.
CAAP and CDC already had a collaborative relationship. Working jointly, CAAP and
CDC initiated HIV sentinel surveillance in Central Asian Republics of Kazakhstan,
Kyrgyzstan, Tajikistan, and Uzbekistan. In addition to sentinel surveillance, CAAP and
CDC also collaborated on laboratory issues in the region.
CDC/Central Asia Regional Office (CAR), based in Kazakhstan, has a long history
of working in the region. It was initially established in 1997 and has been actively
engaged in providing technical assistance to MoHs on HIV/AIDS since 2002. CAAP was
established in 2005 through funding by World Bank and Department for International
Development (DFID). Its main purpose is to control the spread of HIV/AIDS in the
region by engaging stakeholders in the region and by building capacity of local NGOs.
Since prevention of nosocomial infection was an area of overlap between CDC and
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CAAP and because of a history of collaborative efforts between the two entities, both
entities decided to collaborate in area of injection safety as well.
During the discussions between two entities, it was agreed that the Central Asian
countries needed a strategic plan to prevent nosocomial infection. However, the strategy
and implementation plan would be based on country specific needs and in order to better
understand the conditions in individual countries, it was agreed that additional data was
needed.
The first attempt to compile data was using MoHs resources, however, MoHs in
the region have a very weak monitoring and evaluating system. Consequently, the type of
data that was needed did not exist in most of the countries. It was then decided that there
were only two options to gather the necessary data – 1) to conduct rapid assessment in
select sites of each of the country or 2) to conduct national baseline assessment.
During discussions with several other stakeholders, a concern was noted that by
limiting data collection to a specific region of a given country, it may not accurately
represent a national picture. Most of the countries in the region are diverse – their
economic development, infrastructure, and other social phenomenon all vary
considerably. Another concern which was noted that by limiting any assessment to a
specific geographic area, CAAP and CDC may expose healthcare facilities and workers
of those geographic area to national government scrutiny, which may jeopardize the
intent of the assessment. Central Asia has a history of penalizing healthcare workers that
may unintentionally expose patients to risks. Rather than dealing with the root of the
problem, such as in-service/pre-service training of physicians, many countries have
chosen to penalize their health care workers. One such example is Uzbekistan, where in
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2010 a law was passed by the President holding healthcare workers criminally
responsible for spreading HIV in medical facilities. Such laws have rarely resulted in
reduction of nosocomial infection, instead it generally results in resistance by physicians
to diagnose patients with to avoid criminal penalties. Thus, to circumvent both of the
issues, it was decided that data should be collected at the national level. Furthermore, it
was decided that CAAP would provide the funding for the assessments, whereas, CDC
will provide the technical expertise.
The goal identified for the assessment was to collect baseline data in each country
to assess the injection practices in hospitals and lower level health care facilities. It was
agreed that the baseline assessment will be used to identify gaps in the healthcare system
so recommendations could be made to host government on implementation of appropriate
interventions.
Consequently, CAAP and CDC followed-up with each of the Central Asian
Republics, except Turkmenistan. Although no HIV outbreak had been reported in
Turkmenistan, CAAP and CDC wanted to conduct national assessment in Turkmenistan
as well. Officially, the government of Turkmenistan has reported only 2 HIV cases and
does not acknowledge the existence of HIV in their country, which poses significant
challenge in operating there. Despite documentation that other infectious diseases can be
transmitted due to unsafe injection practices, the government of Turkmenistan gave no
response, thus were excluded from this activity.
The MoHs initially only agreed to hold conferences in each country to highlight
and familiarize lead physicians and related public health workers to proper injecting
techniques. After further communications with MoH, it was decided that the goal of the
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conference will be to introduce international guidelines involving injection safety and
related infection prevention and control practices (IPC). Consequently, in June 2009, two
national conferences were conducted in Tajikistan and in Uzbekistan each, and by
September 2009, another two conferences were conducted in Kyrgyzstan and Kazakhstan
each. The conferences were attended by senior representatives of MoHs and included
participants from each oblast (province) of each country. As a result of the conferences
and discussions that took place during the conference, resolutions by the Ministry of
Health were signed that granted CAAP and CDC approval to conduct national
assessments with the goal to improve regulatory documents and national standards.
As the first step towards developing an assessment tool, CDC/Central Asia
Regional office (CDC/CAR) based in Almaty, Kazakhstan took the lead in developing a
protocol and assessment tool for the national assessment in each country. CDC/CAR used
the WHO developed injection safety assessment toolkit as a basis of structuring the
assessment and adapted it to fit the needs of Central Asia. WHO had initially developed a
tool for injection assessment in 2001 (Tool for the assessment of injection safety.
Department of vaccines and biologicals. WHO, Geneva, 2001), but it was revised in 2007
to include all vascular access points, such as intramuscular, subcutaneous and intradermal
practice injections, phlebotomies, intravascular access devices, and procedures with a
lancet (Tool for the assessment of Injection Safety and the Safety of Phlebotomy, Lancet
Procedures, Intravenous Injections and Infusions. SIGN/WHO/Essential Health
Technologies. 16 July, 2007).
Drafts of protocol and assessment tool were shared with the MoHs at various
intervals and many of their recommendations/suggestions were incorporated. Since the
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lingua franca in the region is Russian, the protocol and all the questionnaires were written
in English and translated into Russian when shared with the MoHs for their feedback.
The Russian protocol and questionnaires were also translated back into English and
compared to the original English transcribed protocol and questionnaires to verify
accuracy of translation.
The toolkit was also piloted at a few hospitals to gain feedback from target
audients and participants. The pilot resulted in a few modifications of the questionnaires
to accurately pose the question during the assessment. Once the final changes to the
protocol and toolkit were made, they were submitted to MoHs for their final approval.
MoH approval was received within a few week of the submission, after which it was
submitted to CDC IRB for their approval.
Once IRB approval is received, CDC will hold a two-day training for data
collectors/assessors in each of the country. Data collectors will be trained in a classroom
setting with an introduction to Injection safety and waste management concepts. This
training will include a detailed review of the entire questionnaire including all
instructions and steps. Practice sessions will be held at a local hospital and lower level
facility which are not included in the sample. This will provide an opportunity to
standardize the approach to data collection, to provide feedback on the performance of
data collectors, and to field test the questionnaires in the local context. In the first few
days of the actual data collection, data collectors will receive close support from technical
advisors and hired supervisors to ensure good quality data and to help address any issues
that may arise. Data collectors are to be supervised throughout data collection by
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supervisors; they will be provided with contact information to have immediate access to a
supervisor as needed during data collection.
The report will be written based on the results of the database analysis. It will be
prepared by appropriate CDC staff, and will undergo technical review to ensure the
overall quality of the report. The report will follow the general outline provided to the
analyst and will cover the different topics mentioned in the analysis plan.
The final country-specific survey report will be shared with MoH. MoH will
decide the sharing mechanism with other counterparts. Results may also be presented at
conferences as lessons learned in the following areas (1) need for changing the behavior
of health care workers to ensure safe injection practices through capacity building,
behavior change and communications, and policy interventions; (2) ensuring the
availability of safe injection equipment and supplies through procurement and logistics
interventions; and (3) managing health care waste safely and appropriately; (4)
reduction/elimination of unnecessary injections
The results and the assessment will be presented as a report combined with
information from other countries at a regional workshop for all countries of CAR. This
workshop will include national decision makers, the survey team, directors of large
facilities where assessments were conducted and other national or international agencies
with an interest in the results. Results to be presented will be shown as aggregated results
by CAR region, district or by type of facility (such as grouping all hospitals together, for
example). Data from individual countries will be presented only if there is preceding
approval from the MoH of each country, and even then the name of the country will not
be announced. If a country objects, then all data will be aggregated and shared.
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It is hoped that once the data gained from the assessment will serve as advocacy
tool that can be used to engage host governments in taking actions to prevent nosocomial
infections in the region. The results of the assessment will also guide MoH, CAAP, CDC,
and all stakeholders in developing a strategy that can be implemented in each country to
avoid nosocomial infections in the region.
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DISCLAIMER
This procotol was submitted to CDC for review and approval by IRB, however, at
the time of submission to GSU, the protocol had not been approved by CDC.
Conssequently, the procol may undergo further changes before the assessment
can start.
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ABBREVIATION AND SYMBOLS USED
AIDS – Acquired Immunodeficiency Syndrome
CAR – Central Asia Region
CDC – Centers for Disease Control and Prevention, USA
CDC/CAR - Centers for Disease Control and Prevention, Office in the Central
Asia
CAAP – Central Asian AIDS Project
CVC – Central venous catheter
CV – Curriculum vitae
EPI – Extended Program for Immunization
GAP – Global AIDS Program
HCF – Healthcare facility
HCW – Healthcare worker
HIV - Human Immunodeficiency Virus
HBV - Hepatitis B Virus
HCV – Hepatitis C virus
ICU – Intensive Care Unit
IRB – Institutional Review Board
IS- Injection Safety
MOH – Ministry of Health
PEP – Post-Exposure Prophylaxis
RC AIDS – Republican AIDS Center
RSES – Republican Sanitarian – Epidemiological Station
SIGN – Safe Injection Global Network
TOR – Terms of Reference
WHO – World Health Organization
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This assessment is funded by the Central Asian AIDS Project and is conducted
under the technical assistance of U.S. Centers for Disease Control and
Prevention in cooperation with the Ministries of Health of Kazakhstan,
Kyrgyzstan, Uzbekistan and Tajikistan.
Investigators/Collaborators:
Ministry of Health of Kazakhstan
Republican Sanitarian Epidemiological Station of Kazakhstan
Ministry of Health of Kyrgyzstan
Department of State Sanitarian-Epidemiological Surveillance of Kyrgyzstan
Ministry of Health of Uzbekistan
Department of State Sanitarian-Epidemiological Surveillance of Uzbekistan
Ministry of Health of Tajikistan:
Department of State Sanitarian-Epidemiological Surveillance of Tajikistan
Central Asian AIDS Project
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1. INTRODUCTION
1.1. Literature review
Injections are one of the most common health care procedures. According to
WHO data, there are 16 billion medical injections performed annually in
developing and transitional countries. In countries where unnecessary injections
are common, the average number of health care injections per person has been
estimated to be 3.7 per year (Hauri AM et al., 2003). Half of them are unsafe
injections (see definition, below). The vast majority of injections, about 95%, are
given in curative care
(http://www.who.int/injection_safety/toolbox/en/InjectionFactSheet2002.pdf).
WHO definition of safe medical procedures involving injections or other
parenteral procedures: A safe injection, phlebotomy, lancet procedure or intravenous device
insertion does not harm
the recipient, does not expose the provider to any avoidable risk and does not result in any waste
that is dangerous for other people.”

(http://www.who.int/injection_safety/Injection_safety_final-web.pdf).
The term “injection safety” was initially used when it was recognized that
injections—which are typically thought of as being intramuscular—may be an
important mode of transmission of HIV or hepatitis viruses. More recently, the
term has been broadened to include other means of parenteral injection of
substances (intravenously), withdrawing of blood (phlebotomy) or for
intravenous/intra-arterial access (catheters in veins or arteries). Thus, although
the term used in this protocol is “injection safety,” the safety of additional medical
procedures involving intravascular injection/access will be studied. Injection
safety includes practices intended to prevent transmission of infectious diseases
between one patient and another, or between a patient and healthcare provider,
and also to prevent harms such as needle stick injuries (Joseph F. Perz et al.,
2010).
Injection safety is an important problem around the world. While there is
disagreement among experts over the precise contribution of unsafe injection
practices to global incidence of selected infections, each year, reuse or unsafe
practice of injection devices may cause 20 million infections with hepatitis B virus
(HBV), 2 million infections with hepatitis C virus (HCV), and 250 000 infections
with human immunodeficiency virus (HIV) worldwide, accounting for 30%, 41%
and 5% of new infections in 2000, respectively (Hauri AM et al., 2003). The
probability of transmission of HBV via blood traces on syringes/needles may be
as much as 20-40% in Health Care Facilities (HCF); on average, 6% of needlestick injuries involving HCV-infected patients has led to infection; and
seroconversion risk following HIV-contaminated needle-stick accidents has been
estimated as 0.3% (L. Simonsen A. et al., 1999). Also, improperly handled
injectable medications such as multi-dose vials may transmit blood borne
pathogens (WHO/BCT/DCT 01.02); and the use of multi-dose vials has been
16

reported to be a potential source of infections in 19 studies (L. Simonsen A. et
al., 1999).
Environmental contamination within the HCF is a potential source of infection.
For instance, HBV persists for up to seven days on surfaces (CDC.
Recommendations for preventing transmission of infection among chronic
hemodialysis patients. MMWR, 2001). In Romania, a review of injection practices
revealed that HBV transmission was probably related to the preparation of
injections in contaminated environments (Sautter RL et al., 1984).
There are multiple poor injection practices which could lead to infections. An
example is swabbing of vial tops or ampoules with an antiseptic or disinfectant
when the disinfecting substances have been stored inappropriately (Nakashima
AK et al., 1987; Reiss I et al., 2000). Needle-stick injuries to healthcare workers
when administering injections are usually attributable to the brusque movements
of patients (Jagger J et al., 1998; Haiduven DJ et al., 1992), and ensuring little
movement of the patient or limb is partially preventable. A high proportion of
needle-stick injuries are due to the two-handed recapping technique (Jagger et
al., 1998), a very preventable practice, and unsafe sharps waste collection
causes between 5% and 28% of needle-stick injuries (Khuri-Bulos NA et al.,
1997).
A major concern that places both patient and HCW at risk is unnecessary
injections. Two studies from the United Republic of Tanzania, one of which was a
survey of 66 clinics, concluded that 70% of all curative injections given were
unnecessary (Gumodoka B et al., 1996). An Indonesian survey calculated that
82% of curative injections were unnecessary (Hogeboom van Buggenum et al.,
1993). In India, a study founded that 96% of all injections given by private doctors
were for antibiotics, vitamins and analgesics (Greenhalgh T. et al., 1987). Two
studies in Moscow, Russia concluded that 85% and 99% of injections given to
hospitalized children were unnecessary (Loukina TN et al., 1993; Stekolschikova
IA et al., 1993).
Unsafe injections and vascular access practices are a notable problem for all
CAR countries. All findings mentioned above suggest that unsafe medical
practices remain a significant health threat in Central Asia today. Among them
are unnecessary injections, overuse of transfusions of blood and blood products,
reuse of single use medical equipment, inadequate sterilization, improper
disposal of sharps (e.g., needles, scalpel blades, etc.). An example of a
documented nosocomial HBV and HCV transmission in the region is a CDC/CAR
study of HBV and HCV infection in a TB dispensary in 2002 which found that
10% of HBV susceptible persons seroconvert within three months of beginning
treatment at the dispensary. The seroconversion rate for HCV was similar.
Nosocomial HIV infection cases have been reported from all countries of the
region. One example is the HIV outbreak among children reported in South
17

Kazakhstan oblast (oblasts are the equivalent of States in America) in May 2006.
An epidemiological investigation conducted by CDC/CAR found that the main risk
factors for HIV infection among children during the outbreak were a history of
blood transfusion and certain invasive procedures (subclavian line insertion). A
similar HIV outbreak was reported in the southern part of Kyrgyzstan in 2007.
Also Uzbekistan and Tajikistan have registered cases of nosocomial HIV
infection. Unfortunately, there are no systematically-collected evidence-based
data on injection practices in four of the CAR countries.
WHO developed a tool for the assessment of injection safety in 2001 (Tool for
the assessment of injection safety. Department of vaccines and biologicals.
WHO, Geneva, 2001). Since then, this tool was used in over 90 national injection
safety assessments; results were used to establish national standards for
injection safety. A revised tool has been developed, which includes the
assessment of intramuscular, subcutaneous and intradermal practice injections,
also covers phlebotomies, intravascular access devices, and procedures with a
lancet (Tool for the assessment of Injection Safety and the Safety of Phlebotomy,
Lancet Procedures, Intravenous Injections and Infusions. SIGN/WHO/Essential
Health Technologies. 16 July, 2007).
MOH of have expressed concern about the contribution of hospital acquired
(nosocomial) blood borne infections among registered HIV cases in children in
three of the five Republics. At the present time, MOH of four countries have
expressed the need and willingness to conduct an assessment of injection
practices at the national level with the aim of receiving evidence-based data to
then make decision with the goal of improving national standards and practices.
Last year, CDC and CAAP discussed the best approach with which to provide
technical assistance to each MOH and decided to conduct national conferences
in four Central Asian countries. By June 2009, two national conferences were
conducted, one in Tajikistan and one in Uzbekistan; by September 2009, another
two conferences were conducted, in Kyrgyzstan and Kazakhstan. As a result of
the conferences and discussions in working groups, resolutions by the Ministry of
Health were signed. With the resolution, MOH of all four countries announced the
need for national assessments of injection practices with the aim of using data
from the assessments to improve regulatory documents and national standards
(Prikazes).
1.2. Justification for the assessment
Recognizing from preliminary work that within CAR there is overuse of injections,
unsafe practices, lack of single-use disposable injection equipment in some
countries, and large problems with medical waste management, there is a need
to conduct baseline assessments in at least four of the countries of CAR; a fifth
has not given permission for such a survey. All countries mentioned above will
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require a comprehensive approach toward using the data acquired and applying
them to solving the problems likely to be encountered in the surveys.
1.3. Intended/Potential use of the study
The information collected during this study will provide baseline data on IS and
waste management practices in countries of CAR (Kazakhstan, Kyrgyzstan,
Uzbekistan and Tajikistan). The results of the baseline assessment will allow to
MOHs to improve injection policies and establish an intervention strategy with the
goal of reducing unnecessary injections and improving safe injection practices. A
repeat assessment after implementation and completion of activities for
improvement of injection practices is then anticipated; this study is statistically
powered to allow such an assessment.
2. OBJECTIVES
2.1. Goal and general objectives of the assessment
The goal is to conduct a baseline assessment of injection practices. The
assessment will look for gaps in safe injection practices in hospitals and lower
level HCFs. These identified gaps will be used for improvement of national
policies in injection safety and healthcare waste management, and for the
establishment of educational curricula for pre- and in-service trainings (the
development of training to be also used as a capacity building exercise for MOH
in how to train HCWs, including injection providers and waste handlers).
The general objectives of the assessment include:
1. Assessing the availability of injection equipment/materials.
2. Describing the conditions and practices for administering injections and
other related procedures.
3. Assessing the availability of equipment/materials for the collection,
transport and elimination of waste, as well as the procedures and
practices relative to managing waste from injection and other injectionrelated procedures and activities.
4. Assessing the existence of reference documents (national policy,
standards, and guidelines) in health facilities for injections and other
injection related procedures.
5. Assessing the number of accidental needle sticks among health care
providers and waste handlers reported in the last 6 months.
6. Assessing the barriers to reporting accidental needles sticks among health
care providers.
7. Assessing the knowledge of health care workers about infections
transmitted through unsafe injections and accidental needle sticks.
8. Assessing the vaccination status of the health care providers and waste
handlers (hepatitis B).
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2.2. Specific Objectives and Key Indicators
The survey will seek to answer the following specific questions:
• For each injection given, were the needle and syringe taken from a sterile
pack?
• For each phlebotomy, were the needle and syringe taken from a sterile
pack or was a new phlebotomy set used?
• For each catheter inserted, were the catheter and stylet taken from a
sterile pack?
• For cases where the needle and syringe were NOT taken from a sterile
pack: Was there evidence that a used needle and/or syringe were being
re-used on the same or a different patient without re-processing?
• After the completion of the injection and other injection related procedure,
was the used syringe/device recapped with two hands?
• After each injection and other injection related procedure observed, did
the provider immediately dispose of the used needles and syringes in an
appropriate sharps container or use a needle remover?
Key indicators to assess safe injection practices have been designed to reflect
the goals of the study:
• Key indicators to assess safe intramuscular injection practices
• Use of new sterile devices for injections: “Proportion of intramuscular
injections given with a new syringe and needle”
• Prevention of the risk of needle stick injuries among providers by
eliminating recapping: “proportion of intramuscular injections given by
HCWs who dispose of used sharps involving needles without recapping
them”
• Prevention of the risk for needle stick injuries among HCWs: “Proportion
of intramuscular injections given by HCWs who dispose of used sharps in
a safety box or puncture-proof, leak-proof sharps container (or use a
needle remover) immediately after injection/injection related procedure”
• Key indicators to assess safe intravenous injection practices
• Use of new sterile devices for injections: “Proportion of intravenous
injections given with a new syringe and needle”
• Prevention of the risk of needle stick injuries among providers by
eliminating recapping: “proportion of intravenous injections given by
HCWs who dispose of used sharps involving needles without recapping
them”
• Prevention of the risk for needle stick injuries among HCWs: “Proportion
of intravenous injections given by HCWs who dispose of used sharps in a
safety box or puncture-proof, leak-proof sharps container (or use a needle
remover) immediately after injection/injection related procedure”
• Key indicators to assess safe phlebotomy practices
• Use of new sterile devices for phlebotomies: “Proportion of phlebotomies
given with a new syringe and needle”
20

•

•

•
•
•

•

Prevention of the risk of needle stick injuries among providers by
eliminating recapping: “proportion of phlebotomies given by HCWs who
dispose of used sharps involving needles without recapping them”
Prevention of the risk for needle stick injuries among HCWs: “Proportion
of phlebotomies given by HCWs who dispose of used sharps in a safety
box or puncture-proof, leak-proof sharps container (or use a needle
remover) immediately after injection/injection related procedure”
Key indicators to assess safe IV procedures through CVC and PVC:
Use of new sterile devices for phlebotomies: “Proportion of phlebotomies
given with a new syringe and needle”
Prevention of the risk of needle stick injuries among providers by
eliminating recapping: “proportion of phlebotomies given by HCWs who
dispose of used sharps involving needles without recapping them”
Prevention of the risk for needle stick injuries among HCWs: “Proportion
of phlebotomies given by HCWs who dispose of used sharps in a safety
box or puncture-proof, leak-proof sharps container (or use a needle
remover) immediately after injection/injection related procedure”

3. EXPECTED TYPES OF RESULTS
The results expected at the end of the baseline assessment are listed below:
3.1. In the area of managing injection equipment and waste management
products, data will be collected on:
• The length of time that injection commodities or equipment or safety
boxes are out of stock
• The appropriate amount of injection equipment and safety boxes available
in the inventory by type and by size
3.2. In the area of injection administration, data will be collected on:
• Packaging of the injection equipment (new and sterile package)
• The reconstitution of medications/ vaccines
• Cleaning or use of an antiseptic at the injection site prior to administration
• The practice of ‘‘re-capping’’ needles after injection
• The use of safety boxes to collect used injection equipment
(syringes/needles) (see appendix 3, section 1, Q 1.07)
• The use of needle removers on used injection equipment
• Training on injection safety
3.3. In the area of infection prevention and control, data will be collected
on:
• The hygienic conditions of injection preparation and administration (see
appendix 3, Section 3, Q 3.1.)
• The hand hygiene practice of HCWs administering the injection
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•
•
•

The number of accidental needle sticks among health care providers and
waste handlers reported in the last 6 months
The knowledge of health care workers of infections transmitted through
unsafe injections and accidental needle sticks
The vaccination status of the health care providers and waste handlers
(hepatitis B)

3.4. In the area of estimating needs relative to injection safety, data will be
collected on:
• The existence of reference documents on injection safety (national policy,
standards and guidelines)
• Forecasting adequacy-the regularity of the supply of products, injection
equipment and waste management materials
• The adequacy of the amounts on-site of injectable products, injection
equipment, waste management material
3.5. In the area of medical waste management, data will be collected on:
• Medical waste-final disposal methods
• Method of eliminating ashes following incineration (if there is an
incinerator)
• Maintenance of the incinerator (if there is an incinerator)
• Problems encountered relative to final medical waste disposal
• Vaccination status of the health workers responsible for waste
management (hepatitis B)
• Type of protective equipment available and used
• Training in medical waste management
4. MATERIALS AND METHODS
4. 1. Type and Duration of the Survey
All assessments are cross-sectional surveys. The assessments in Kazakhstan
and Kyrgyzstan are being performed with HCF’s that will be randomly selected,
while the assessments in Tajikistan and Uzbekistan will be done in preselected
HCFs (lists of HCFs are provided by MOHs). Data will be gathered via interviews
with facility staff, facility-based observations, and review of stock and inventories
of materials in the visited HCFs.
The total duration of the assessment starting with training for assessors and
finishing with the production of the final report is described in Appendix 1.
4.2. Units of Analysis and Target Populations
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The unit and target populations of the injection safety assessment include the
following:
• Survey Units
The sample will be stratified by facility type to include the following (tailored as
appropriate to the country work plan and expansion plan):
• Oblast-level and city-level hospitals, and polyclinics
• Adult hospitals: intensive care, theraputical, surgical, obstetrics,
outpatient and laboratory
• Pediatric hospitals: intensive care, theraputical, surgical, outpatient and
laboratory
• Rayon-level hospitals (no separate hospitals for adult and pediatric
services)
• Departments: intensive care, therapeutical, surgical, obstetrics,
pediatric, outpatient and laboratory.
• Public health centers, health posts in the rayon level villages (primary
health care services).
• Tertiary hospitals (specific for Uzbekistan, as provided by MoH).
• Target Populations
The target populations are selected staff and patients of the following types:
• Staff administering injections and phlebotomy
• Supervisors of the staff responsible for administering injections and
phlebotomy
• Staff in charge of medical waste management
• Patients of observed departments/facilities
4.3. Sample Size Calculations
This is proposed study protocol for four countries of CAR and thus sample size
calculations presented here are country-specific.
Nevertheless, types of procedures and types of HCFs will be same for all
countries (table 1).
Table 1. Health care services included in assessment and types of
procedures.
Service
Outpatient Services:
All diagnostic, curative and preventive
Hospitals:
Theraputical, surgical, obstetricgynecological, pediatric, laboratory,

Procedures
1. Injections – IM, IV
2. IV infusions
3. Phlebotomies
1. IM injections
2. IV Injections
3. IV infusions, including these
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ICU, outpatient departments
LL HCFs:
Both curative and vaccination

through CVC and PVC
4. Phlebotomies
1. IM/SC
2. IV injections

Kazakhstan and Kyrgyzstan
The objective of the study, as stated above in Section 2, is to assess injection
practices in hospitals as well as lower-level facilities in the country. Statistical
testing is planned for the comparisons of data acquired from the baseline
assessment, listed in Section 4.4.
The sampling unit is the HCF. Two-stage, cluster-sampling self method through
choice in which clusters are selected using probability proportional to population
size and equal numbers of sampling units within each cluster. As clusters, rayons
and cities were selected. There are a finite number of HCFs in the clusters
covered by this survey. Ten HCFs per cluster were selected, including 2 oblast
level HCFs to which rayon belongs. We are going to observe four types of
injections and related procedures: phlebotomies, IV and IM injections, IV
infusions, including these through CVC and PVC. We assume a design effect of
2.0, beta of 0.80 and alpha of 0.05 and calculated the sample sizes as described
below using the Power and Sample Size (PASS) software package
For the four types of procedures, we assume (in the absence of data) that 15% of
each procedure is unsafe. We assume that our intervention will decrease the
proportion of unsafe procedures to 5% after intervention. We calculate a sample
size of 320 observations for each procedure. We estimate that two injections (2
curative and 2 immunization) will be observed in each lower-level facility and
eight procedures 2 IM, 2 IV, 2 phlebotomies, 2 IV infusions, including these
through CVC and PVC, in each of up to seven (7) departments of each of the
selected hospitals. These injection observations will be used to evaluate key
indicators (table 2a and 2b).
In terms of CVCs, we assume (in the absence of data) that 30% of them are
unsafe during baseline assessment. We assume that our intervention—if it is to
have a “significant” impact on the proportion of unsafe practices--will decrease
the proportion of unsafe CVCs to 5% after intervention. We calculate a sample
size of observations for catheterizations of 78 per country. Although we are
interested in CVCs, we believe it will difficult to observe enough number of
procedures, uncertainty about number and timing of CVC insertion at the
facilities, and the length of time (minimum, 25 minutes) required to observe a
complete CVC procedure. We will prioritize CVC observation in our visits and
learn what we can, although we are uncertain we can achieve the hoped-for
number of 78 observations.
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The allocated number of injection observations for each of the four procedures by
rayon will, unlike for CVC, far exceed the calculated sample size. Given this,
injection practices may be analyzed and then presented by higher-level facility
(hospital) and lower-level facilities (medical post), provided there are enough
cases in each for this level of analysis but such a comparison is not a primary
intent of our study.
Uzbekistan and Tajikistan
As it was mentioned above, the MOHs of both countries chose not to use random
sampling and, instead, provided CAAP and CDC with preselected list of HCFs.
We believe that the assessment of practices using the lists provided by MOHs
will provide valuable information.
The sampling unit is the HCF. These HCFs include oblast hospitals, rayon
hospitals, city level hospitals/District hospitals (which are lower-level hospitals)
and outpatient clinics or LL HCFs (Medical posts) as well. For Uzbekistan, MOH
also selected tertiary hospitals.
For Uzbekistan, in which we used 75 HCFs given to us by the country, we have
no good way of knowing how representative they are of all HCFs. But, every
oblast is represented in the sample with at least one HCF and a range of types of
HCFs is included, i.e., oblast level, rayon-level and lower level.
For Tajikistan, in which we used sample of 106 HCFs given to us, all oblast- and
rayon-level hospitals were included, as were a variety of lower-level facilities. To
attempt to obtain a representative “picture” of practices, a sample will be drawn
from across the study area. It is estimated that four injections (2 curative and 2
immunization) will be observed in each lower-level facility and six (2 IM, 2 IV and
2 phlebotomies) in each one of up to seven (7) departments of each of the
selected hospitals. These injection observations will be used to evaluate key
indicators (table 2c and 2d).
4.4. Sampling Techniques in Health Districts and Health Facilities
Kazakhstan and Kyrgyzstan
The sampling of health facilities assessed will be obtained through a combination
of purposeful and random selection. In each cluster to be assessed, the following
approach will be used:
• Oblasts are listed haphazardly (using a listing provided by Ministry, which
was not alphabetical and Ministry did not know the intent of use of the list)
with all their rayons. .
• The initial rayon is to be selected by random number from the listing of
oblast/rayons. This rayon belongs to an oblast and defines the oblast that
will be included in the study.
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•

•
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Purposeful selection will be used for selecting oblast hospitals, rayon
hospitals, and lower-level hospitals (so that oblast level, rayon level, and
lower-level hospitals are included). There are 1-2 oblast hospitals, 1
(occasionally 2) rayon-level hospitals, and generally lower-level hospitals.
All will be included, because it is in hospitals that injections or catheters
are used. Selecting lower-level primary HCFs (see next bullet) runs the
risk of identifying a HCF but in which there may be no procedures being
done the day of the visit.
Random sampling will then be used for selecting lower-level primary
HCFs, using a computer-generated random number selection. Nine is
generally considered to be a reasonable number of facilities in an
assessment of this type and we shall select 10. Each unit of analysis
should have this number of facilities at a minimum.
The second rayon is then selected by PPS and the above process
repeats. The sampling interval was the entire population of the country
divided by 8. We applied the sampling interval to the cumulative
population in the Excel sheet (as described in the first bullet) to select the
next rayon. We then repeated the process just described. Our goal was
to get 80 HCFs, and to always have the oblast-level, rayon-level, and
lower-level hospitals and, then, primary care HCFs.
Attached (Appendix 8 KZ sampling.doc and Appendix 9 KG sampling.xls)
are files that contain the sampling schemes.

Observations or syringe use for injections and phlebotomy will be conducted in
the hospital service areas where the majority of syringes and needles are used.
In Central Asia health care facilities perform procedures such as phlebotomy,
injection and catheter insertion in special areas. These include: ICU, medical
department, pediatrics, gynecology-obstetrics, outpatient care, the phlebotomy
area of the laboratory, and surgical ward1, as well as stock room of each
department. It is important to note that not all hospitals will have all seven
departments. The survey will include all of the areas listed above that exist at
each facility.2
The assessment will be carried out in the health districts and numbers of facilities
in Kazakhstan and Kyrgyzstan is shown in Table 1a and b.

1

Surgical department is listed as an area but it should be noted that this refers to pre-operative
procedures and post-operative procedures. Data collectors will not attempt to observe actual
surgeries.
2
The specific types of service departments may vary by hospital. The goal is to include all areas
with high numbers of injections or use of injection equipment as well as the stock room. While it
is recognized that there may be other locations where injections can occasionally be observed, it
is not necessary to visit those areas for this quantitative data collection. However, those areas
can and should be visited during supervisory visits. Dental clinics are not a suggested location
for data collection because there are usually too few of them for quantitative analysis. Trauma
centers and psychiatric departments are not recommended sites of data collection because the
data collectors risk interfering with patient treatment.
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Uzbekistan and Tajikistan
Assessment will be done in preselected HCFs. Observations of needle/syringe
use for injections and phlebotomy will be conducted in the seven departments
where the majority of syringes and needles are used. These include: ICU,
medical department, pediatrics, gynecology-obstetrics, outpatient care, the
phlebotomy area of the laboratory, and surgical, as well as stock room of each
department. It is important to note that not all hospitals will have all seven
departments. The survey will include all of the areas listed above that exist at
each facility.
Table 1a: Health Districts and Facilities in Kazakhstan to be Covered
by This Survey
Districts
# Oblast #
#
# LL # City
#
Tota
hospital Rayon
District HCF hospita Outpatie l #
s*
hospita hospita s
ls
nt clinics of
ls
ls
HCF
s
10
1
1
2
6
0
0
Ulansky
rayon (East
Kazakhsta
n Oblast)
10
2
2
0
6
0
0
Shetsky
rayon
(Karagand
a)
10
2
0
1
3
1
3
Ekibaztuz
city
(Pavlodar
oblast)
10
1
1
5
0
1
Astrakhans 2
ky rayon
(Akmola
Oblast)
10
4
0
0
0
5
Makhtarals 1
ky rayon
(SKO)
10
1
0
0
2
5
2
Shymkent
city (SKO)
10
1
4
3
0
0
Kurmangaz 2
y rayon
(Atyrau
oblast)
10
0
0
0
0
5
5
Almaty
11
9
8
25
11
16
80
Total
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* For each oblast it can have 1 or 2 oblast hospitals; no oblast has more
than 2 hospitals.
Table 1b: Health Districts and Facilities in Kyrgyzstan to be Covered
by This Survey
Districts

# Oblast
hospital
s*

#
Rayon
hospita
ls

#
District
hospita
ls

# LL
HCF
s

# City
hospita
ls

#
Outpatie
nt
clinics

Tota
l#
of
HCF
s

10
1
1
2
5
0
1
Sokoluk
(Chu oblast)
11
2
2
5
0
0
2
Batken
(Kadamjay)
10
1
1
0
6
0
2
Talas
(Karabura)
10
2
3
0
4
0
1
Aravan
(Osh)
10
0
8
0
0
0
2
Nookat
(Osh)
10
1
1
0
7
0
1
Jalalabat
(Bazarkurga
n)
9
1
0
0
4
2
2
Issyk-Kul
10
0
0
0
0
3
7
Bishkek
8
16
7
26
5
18
80
Total
* For each oblast it can have 1 or 2 oblast hospitals; no oblast has more
than 2 hospitals.

The lists of HCFs for Kazakhstan, Kyrgyzstan, Uzbekistan and Tajikistan
are presented in Appendix 2.
4.5. Study Populations / Areas
A description of data to be collected from each study population/area can be
found below. Details for can be found in Table 3 at the end of this section.
4.5.1 Inventory / Stock Rooms
Each stock room of each department of each hospital (7 departments will
be under observation or, if fewer than 7 departments exist, as many as do
exist) and each procedure site within each department hand stock will be
assessed. In LLHCFs, 1 stock room will be assessed. In total, 7 stock
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rooms per hospital (or, if fewer, if there are fewer than 7 departments) and
1 stock room per LLF will be assessed.
4.5.2 Observation of departments and entire HCFs
The observations are conducted in and around the facility and compiled
onto 1 questionnaire. Observations outside the facility are limited to the
facility grounds. A total of 1 set of observations covering the entire hospital
and 1 set of observations per lower-level facility will be completed. These
observations will be analyzed by department with a total of 7 sets of
observations per hospital and 1 per lower-level facility in each country.
Thus, 7 departments or fewer will be observed per hospital. One
department of each type (general, ICU, surgical, obstetric, pediatric,
laboratory and outpatient) well be assessed. If, however, a hospital has 3
departments of one type, only one department will be chosen randomly for
assessment. If there are more than two departments of one type, the
number of these departments will be placed into “a hat” and randomly
draw one from the hat; if there are two, assessors will flip a coin.
4.5.3 Injections Observed
The observations are conducted where the injections are given (patient
bedside, injection room, etc). Usually, these services are concentrated in
one or two rooms in lower level facilities. Data will be collected in both
inpatient and outpatient settings. In hospitals, observations will be
conducted in the departments listed in Section 4.4. If more than one
HCW is providing procedures during observations, all HCWs will be
observed. Although four injection observations are planned for each lowerlevel facility and eight injection observations per each department of each
hospital, there will be fewer observations if not all hospitals have all 7
departments or if some lower-level facilities or hospital departments have
fewer than 4 injections taking place during the time of the data collection
visit.
Kazakhstan
A sampling of injections observed will be devised in the following manner:
•

Hospitals: 8 injections and related procedures per service
area (department), that is, 8 in medicine, 8 in pediatrics, 8 in
gynecology-obstetrics, 8 in surgical , 8 in the laboratory, 8 in ICU
and 8 in the outpatient department (8 injections per service area
x 7 departments x 39 hospitals). Total: 2,184 injections will be
observed.
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•

City outpatient clinics: 8 injections per service area
(department), that is, 8 in laboratory and 8 injections where
patients receive treatment (8 injections per service area x 2
service areas x 16 HCFs). Total 256 injections will be observed.

•

Lower-level health facilities: 4 injections per facility of which
2 should be a vaccination, 2 curative3. Note that the goal is to
observe 4 injections. Data collectors should observe no more
than 2 immunizations and 2 curative injections. (4 injections per
facility x 25 HCFs). Total: 100 injections will be observed (see
Table 2).

Table 2a: Total number of procedures to be observed in HCFs,
Kazakhstan.
HCFs

# of
HCFs

Hospitals
City outpatient clinics
Lower level HCFs
Total

39
16
25
80

# of
# of
departments procedures
per
department
7
8
2
8
1
4

Total # of
procedures

2184
256
100
2540

Kyrgyzstan
A sampling of injections observed will be devised in the following manner:
•

Hospitals: 8 injections per service area (department), that is,
8 in medicine, 8 in pediatrics, 8 in gynecology-obstetrics, 8 in
surgical , 8 in the laboratory, 8 in ICU and 8 in the outpatient
department (8 injections per service area x 7 service areas x 36
hospitals). Total 2016 injections will be observed.

•

City outpatient clinics: 8 injections per service area
(department), that is, 8 in laboratory and 8 in s where patients
receive treatment (8 injections per service area x 2 service
areas x 18 HCFs). Total 288 injections will be observed.

•

Lower-level health facilities: 4 injections per facility of which
2 should be a vaccination, 2 curative. Note that the goal is to

3

The purpose of this is to have a sample of each type of HCF and practices for analysis. This way will
allow us to have national wide data.
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observe 4 injections. Data collectors should observe no more
than 2 immunizations and 2 curative injections. (4 injections per
facility x 26 HCFs). Total 104 injections will be observed (see
Table 2b).
Table 2b: Total number of procedures to be observed in HCFs,
Kyrgyzstan.
HCFs

# of
HCFs

Hospitals
City outpatient clinics
Lower level HCFs
Total

36
18
26
80

# of
# of
departments procedures
per
department
7
8
2
8
1
4

Total # of
procedures

2016
288
104
2408

Uzbekistan
A sampling of injections observed will be devised in the following manner:
•

Hospitals: 8 injections per service area (department), that is,
8 in medicine, 8 in pediatrics, 8 in gynecology-obstetrics, 8 in
surgical , 8 in the laboratory, 8 in ICU and 8 in the outpatient
department (8 injections per service area x 7 service areas x 65
hospitals). Total 3640 injections will be observed.

•

City outpatient clinics: 8 injections per service area
(department), that is, 6 in laboratory and 6 in s where patients
receive treatment (8 injections per service area x 2 service
areas x 4HCFs). Total 64 injections will be observed.

•

Lower-level health facilities: 4 injections per facility of which
2 should be a vaccination, 2 curative. Note that the goal is to
observe 4 injections. Data collectors should observe no more
than 2 immunizations and 2 curative injections. (4 injections per
facility x 6 HCFs). Total 24 injections will be observed (see
Table 2c).

Table 2c: Total number of procedures to be observed in HCFs,
Uzbekistan.
HCFs

# of
HCFs

# of
# of
Total # of
departments procedures procedures
per
department
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Hospitals
City outpatient clinics
Lower level HCFs
Total

65
4
6
75

7
2
1

8
8
4

3640
64
24
3728

Tajikistan
A sampling of injections observed will be devised in the following manner:
•

Hospitals: 8 injections per service area (department), that is,
8 in medicine, 8 in pediatrics, 8 in gynecology-obstetrics, 8 in
surgical , 8 in the laboratory, 8 in ICU and 8 in the outpatient
department (8 injections per service area x 7 service areas x 28
hospitals). Total 1624 injections will be observed.

•

City outpatient clinics: 8 injections per service area
(department), that is, 8 in laboratory and 8 in s where patients
receive treatment (8 injections per service area x 8 service
areas x 25HCFs). Total 400 injections will be observed.

•

Lower-level health facilities: 4 injections per facility of which
2 should be a vaccination, 2 curative. Note that the goal is to
observe 4 injections. Data collectors should observe no more
than 2 immunizations and 2 curative injections. (4 injections per
facility x 53 HCFs). Total 212 injections will be observed (see
Table 2d).

Table 2d: Total number of procedures to be observed in HCFs,
Tajikistan.
HCFs

# of
HCFs

Hospitals
City outpatient clinics
Lower level HCFs
Total

29
25
53
106

# of
# of
departments procedures
per
department
7
8
2
8
1
4

Total # of
procedures

1624
400
212
2236

4.5.4 Injection Administrators
A single person (“injection administrator”) performing injections within each
department will be chosen for the injection provider interview. This is a
quota/convenience sample of one. The injection administrator to be
interviewed will be the health worker who administers the largest number
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of injections being observed on the day of data collection in each facility
(or, in the case of the laboratories, the one who uses the largest numbers
of devices to draw blood). Usually, this will be the treatment room nurse in
each department or the laboratory technician responsible for blood
drawing.
Kazakhstan:
Injection providers will be sampled according to the following
breakdown:
•

Hospitals: 1 participant per service area: 1 in the medical
department, 1 in pediatrics, 1 in gynecology-obstetrics, 1 in surgical , 1
in ICU , 1 in the laboratory, and 1 in the outpatient department. (7
participants x 39hospitals). Total 273 participants.

•

City outpatient clinics: 1 participant per service area: 1 in the
laboratory and 1 in for treatment. (2 participants x 16 HCFs). Total 32
participants.

•

Lower-level facilities4: 1 participant per facility (1 participant x 25
facilities). Total 25 participants.

Kyrgyzstan:
Injection providers will be sampled according to the following
breakdown:
•

Hospitals: 1 participant per service area: 1 in the medical
department, 1 in pediatrics, 1 in gynecology-obstetrics, 1 in surgical , 1
in ICU , 1 in the laboratory, and 1 in the outpatient department. (7
participants x 36 hospitals). Total 252 participants.

•

City outpatient clinics: 1 participant per service area: 1 in the
laboratory and 1 in department for treatment. (2 participants x 18
HCFs). Total 36 participants.

•

Lower-level facilities: 1 participant per facility (1 participant x 26
facilities). Total 26 participants.

4

If the configuration of a lower-level facility is such that there are essentially two separate departments,
each with its own staff, then it may be possible to take 1 participant from each department. For example, if
there are urban health centers, each of which has an outpatient area and a maternity area with its own staff,
it would be possible to select 1 participant in the outpatient area and 1 in the maternity department. This
approach would double the number of participants in the facility, as currently only one participant per
facility is planned.
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Uzbekistan
Injection providers will be sampled according to the following
breakdown:
•

Hospitals: 1 participant per service area: 1 in the medical
department, 1 in pediatrics, 1 in gynecology-obstetrics, 1 in surgical
department, 1 in ICU , 1 in the laboratory, and 1 in the outpatient
department. (7 participants x 65 hospitals). Total 455 participants.

•

City outpatient clinics: 1 participant per service area: 1 in the
laboratory and 1 in department for treatment. (2 participants x 4 HCFs).
Total 8 participants.

•

Lower-level facilities: 1 participant per facility (1 participant x 6
facilities). Total 6 participants.

Tajikistan
Injection providers will be sampled according to the following
breakdown:
•

Hospitals: 1 participant per service area: 1 in the medical
department, 1 in pediatrics, 1 in gynecology-obstetrics, 1 in surgical
department, 1 in ICU , 1 in the laboratory, and 1 in the outpatient
department. (7 participants x 28 hospitals). Total 196 participants.

•

City outpatient clinics: 1 participant per service area: 1 in the
laboratory and 1 in department for treatment. (2 participants x 25 HCFs).
Total 50 participants.

•

Lower-level facilities: 1 participant per facility (1 participant x 53
facilities). Total 53 participants.
4.5.5 Supervisors of injection providers
Kazakhstan
Supervisors of the staff responsible for administering injections or blood
draws will be selected according to the following breakdown:
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•

Hospitals: 1 participant per service area: 1 supervisor in the medical
department, 1 in pediatrics, 1 gynecology-obstetrics, 1 in surgical
department, 1 in ICU, 1 in the laboratory, and 1 in the outpatient
department (7 participants x 39 hospitals). Total 273 participants.

•

City outpatient clinics: 1 participant per service area: 1 supervisor
in the laboratory and 1 in department where treatment is provided. (2
participants x 16 HCFs). Total 32 participants

•

Lower-level facilities: 1 participant per facility (1 participant x 25
facilities). Total 25 participants.

Kyrgyzstan
Supervisors of the staff responsible for administering injections or blood
draws will be selected according to the following breakdown:
•

Hospitals: 1 participant per service area: 1 supervisor in the medical
department, 1 in pediatrics, 1 gynecology-obstetrics, 1 in surgical , 1 in
ICU, 1 in the laboratory, and 1 in the outpatient department (7
participants x 36 hospitals). Total 252participants.

•

City outpatient clinics: 1 participant per service area: 1 supervisor
in the laboratory and 1 in department where treatment is provided. (2
participants x 18 HCFs). Total 36 participants

•

Lower-level facilities: 1 participant per facility (1 participant x 26
facilities). Total 26 participants.

Uzbekistan
Supervisors of the staff responsible for administering injections or blood
draws will be selected according to the following breakdown:
•

Hospitals: 1 participant per service area: 1 supervisor in the medical
department, 1 in pediatrics, 1 gynecology-obstetrics, 1 in surgical
department, 1 in ICU, 1 in the laboratory, and 1 in the outpatient
department (7 participants x 65 hospitals). Total 455 participants.

•

City outpatient clinics: 1 participant per service area: 1 supervisor
in the laboratory and 1 in department, where treatment is provided. (2
participants x 4 HCFs). Total 8 participants

•

Lower-level facilities: 1 participant per facility (1 participant x 6
facilities). Total 6 participants.
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Tajikistan
Supervisors of the staff responsible for administering injections or blood
draws will be selected according to the following breakdown:
•

Hospitals: 1 participant per service area: 1 supervisor in the medical
department, 1 in pediatrics, 1 gynecology-obstetrics, 1 in surgical
department, 1 in ICU, 1 in the laboratory, and 1 in the outpatient
department (7 participants x 28 hospitals). Total 196 participants.

•

City outpatient clinics: 1 participant per service area: 1 supervisor
in the laboratory and 1 in department, where treatment is provided. (2
participants x 25 HCFs). Total 50 participants

•

Lower-level facilities: 1 participant per facility (1 participant x 53
facilities). Total 53 participants.

4.5.6 Staff in charge of waste management
Kazakhstan and Kyrgyzstan
Among staff responsible for waste management, only the main person
responsible for waste management will be interviewed. So, 1 participant
per hospital and 1 participant per lower-level facility will be selected
for interview. Total: 80 participants per country will be selected for
interview.
Uzbekistan and Tajikistan
Among staff responsible for waste management, only main person
responsible for waste management will be interviewed. So, 1 participant
per hospital and 1 participant per lower-level facility will be selected
for interview. Total: 75 participants in Uzbekistan and 106 participants in
Tajikistan will be interviewed.
4.5.7 Patients, hospitalized in the observed departments
Kazakhstan
Patients receiving medical care in these healthcare facilities will be
selected for interview according following breakdown.
• Hospitals: 4 participants per service area: 4 patients in the medical
department, 4 parents in pediatrics, 4 patients in gynecologyobstetrics, 4 patients in surgical, 4 patients in outpatient department, 4
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patients in laboratory, excluding ICU (4 participants x 6 departments x
36 hospitals). Total 864 participants.
•

City outpatient clinics: 4 participants per service area: 4 patients
in the laboratory and 4 in department, where treatment is provided. (8
participants x 16 HCFs). Total 128 participants

•

Lower-level facilities: 2 participants per facility (2 participant x 25
facilities). Total 50 participants.

Kyrgyzstan
Patients receiving medical care in these healthcare facilities will be
selected for interview according following breakdown.
• Hospitals: 4 participants per service area: 4 patients in the medical
department, 4 parents in pediatrics, 4 patients in gynecologyobstetrics, 4 patients in surgical department, 4 patients in outpatient
department and 4 patients in laboratory, excluding ICU (4 participants x
6 departments x 36 hospitals). Total 864 participants.
•

City outpatient clinics: 4 participants per service area: 4 patients
in the laboratory and 4 in department, where treatment is provided. (8
participants x 18 HCFs). Total 144 participants

•

Lower-level facilities: 2 participants per facility (2 participant x 25
facilities). Total 52 participants.

Uzbekistan
Patients receiving medical care in these healthcare facilities will be
selected for interview according following breakdown.
• Hospitals: 4 participants per service area: 4 patients in the medical
department, 4 parents in pediatrics, 4 gynecology-obstetrics, 4 in
surgical department, 4 patients in outpatient department and 4 patients
in laboratory, excluding ICU (4 participants x 6departments x 65
hospitals). Total 1560 participants.
•

City outpatient clinics: 4 participants per service area: 4 patients
in the laboratory and 4 in department, where treatment is provided. (8
participants x 4 HCFs). Total 32 participants

Lower-level facilities: 2 participants per facility (2 participant x 6
facilities). Total 12 participants.
Tajikistan
•
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Patients receiving medical care in these healthcare facilities will be
selected for interview according following breakdown.
• Hospitals: 4 participants per service area: 4 patients in the medical
department, 4 parents in pediatrics, 4 patients in gynecologyobstetrics, 4 patients in surgical department, 4 patients in outpatient
department and 4 patients in laboratory, excluding ICU (4 participants x
6 departments x 28 hospitals). Total 672 participants.
•

City outpatient clinics: 4 participants per service area: 4 patients
in the laboratory and 4 in department, where treatment is provided. (8
participants x 25 HCFs). Total 200 participants

•

Lower-level facilities: 2 participants per facility (2 participant x 53
facilities). Total 106 participants.

Table 3a: Target Population Sample for Kazakhstan

# Target Population
1
2
3
4
5
6
7

Stock room inventory
HCF observations
Observations of injections or phlebotomy
Injection administrator interviews
Interviews with supervisors of injection
administrators
Waste management interviews
Patients

Sample size
Hospitals City
outpatient
273
32
39
16
2184
256
273
32
273
32

LL HCFs

Total

25
25
100
25
25

329
80
2540
330
330

39
864

25
50

80
1042

16
128

Table 3b: Target Population Sample for Kyrgyzstan

# Target Population
1
2
3
4
5
6
7

Stock room inventory
HCF observations
Observations of injections or phlebotomy
Injection administrator interviews
Interviews with supervisors of injection
administrators
Waste management interviews
Patients

Sample size
Hospitals City
outpatient
252
36
36
18
2016
288
252
36
252
36

LL HCFs

Total

26
26
104
26
26

314
80
2408
314
80

36
864

26
52

80
1060

18
144

Table 3c: Target Population Sample for Uzbekistan

38

# Target Population
1
2
3
4
5
6
7

Stock room inventory
HCF observations
Observations of injections or phlebotomy
Injection administrator interviews
Interviews with supervisors of injection
administrators
Waste management interviews
Patients

Sample size
Hospitals City
outpatient
455
8
65
4
3640
64
455
8
455
8

LL HCFs

Total

6
6
24
6
6

469
75
3728
469
75

65
1560

6
12

75
1604

4
32

Table 3d: Target Population Sample for Tajikistan

# Target Population
1
2
3
4
5
6
7

Stock room inventory
HCF observations
Observations of injections or phlebotomy
Injection administrator interviews
Interviews with supervisors of injection
administrators
Waste management interviews
Patients

Sample size
Hospitals City
outpatient
196
50
28
25
1624
400
196
50
196
50

LL HCFs

Total

53
53
212
53
53

299
106
2236
299
299

28
672

53
106

106
978

25
200

4.6. Data Collection
Teams will visit an average of 1 hospital or 2 lower-level facilities per day. The
estimated number of days for data collection in the field for each country is as
follows:
This activity will be carried out using the assessment tools adapted to the context
of the health system. The assessment tools are questionnaires with 6
components or ‘‘Sections’’ that relate to specific intervention areas of injection
safety. (See Appendices 3 under separate cover.) These sections are:
•
•
•
•
•
•

Inventory/stock rooms: Section 1
Observations of health facilities and waste management: Section 2
Observations of injection practices: Section 3
Interviews of injection providers: Section 4
Interviews with supervisors of injection providers: Section 5
Interviews with waste management staff: Section 6
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•

Interviews of patients: Section 7

Data will be collected by 12 people. There will be 4 teams consisting of, on
average, 3 people consisting of 2 data collectors and 1 team leader. Generally,
there will be one data collection team per 2 districts.
4.6.1 Respondent selection
Respondents will be selected according to the specific criteria
detailed below:
• In each department, if more than one HCW provides procedures the
provider who gives the most injections will be selected for interview
(“injection administrator”). The data collector will ask the individual health
care workers for their permission to be observed prior to the interview.
• If the injection provider who was interviewed has a supervisor in the
department at the time of the survey, this person is to be selected for the
supervisor interview. Head nurse of observed department would be
preferable as supervisor for interview. In case the head nurse is not
available, the head doctor could be interviewed as a supervisor. If the
provider does not have a supervisor, another injection provider will be
interviewed; or if none is available at the time of the survey, the questions
are asked of the injection provider.
• Only one waste handler is to be interviewed in each facility .The surveyor
should select the waste handler who is the primary person in charge of
managing health care waste.
• Patients in departments in hospital will be selected randomly from the list
of patients hospitalized into observing department, excluding ICU patients.
In city outpatient clinics and LL HCF any patient in turn will be selected for
interview. In case if only children are receiving vaccinations at time of
observation, their relatives who are accompanying them will be selected
for interview.
4.6.2 Confidentiality protections
To ensure confidentiality protection prior to conducting interviews, an informed
consent will be read to the respondent and signed by the interviewer with no
health care worker or patient identifying information. There is potential risk to the
participant from signing a consent form. Potentially risky practices will be
observed and the consent form will be the only objective link of participants to
having participated in the assessment. Thus, we believe a waiver of signed
consent is justified. If the person refuses to participate, the data collector will
accept the refusal and record that a potential participant has declined. Also
participants will have a clear choice to leave the interview at any time. Data
collectors will ensure that HCW’s or patient’s interviews are conducted in a
private setting where they will not be overheard by facility health care staff or
anyone else. Data collection will involve adults only and data collected will not be
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identifiable. To minimize risk to the participant, data collected will not include any
identifying information and will only be handled by the study team. Data will be
presented publicly in aggregate form (by district, by type of facility, and by
department in hospitals.) Results presented in the report are not linked to
individual facilities where data are collected, so they are not traceable to
individual respondents. (See Appendix 4 for Sample Informed Consent Forms).
4.6.3 Other ethical concerns/issues
We will take ensure risks to participants are minimized and
information is kept confidential such as holding interviews in a
private setting where they will not be overheard by other facility
health care staff, supervisors, or anyone else. Specific risks and
protections are detailed below:
Health care workers that are observed giving injections or conducting
phlebotomy will also be interviewed to find out if they have ever had a needle
stick injury, what diseases they are aware of that can be transmitted by needle
stick injuries, and their HBV vaccination status. This activity is similar to
supervisory visits and the risk to the employment position of the respondent is
minimal. Data collectors will not collect the names or other information to identify
the health care worker being interviewed or observed and will ask individual
HCWs for their permission to observe procedures. If HCWs experience a needle
stick injury during the observation or disclose during the interview that one was
suffered within the preceding seven days (arbitrarily determined by the
likelihood of successful interventions, e.g., HBV vaccination, ART prophylaxis,
patient being accessible) the study team will be able to provide participants
information and correct referrals for post-exposure prophylaxis (PEP) within the
facility where the health worker is currently employed. This is to ensure that if a
HCW reports a needle stick or other occupational exposure to BBP, they can be
quickly referred to the appropriate person or service. This arrangement will be
made before research activities take place in collaboration with the health facility
infection prevention and control specialist. .
• Surveyors will be trained to tactfully interrupt any health care workers who
may be about to re-use syringes and needles prior to them endangering
patients; training will be provided on when to intervene. In case of such
intervention no more injections will be observed for this healthcare worker.
In this case, observation of another HCW will begin to complete
observation of the required number of procedures.
• Patients receiving injections may need to remove clothing to expose
injection sites. The possible risks of embarrassment or worry are not
expected to outweigh the potential benefits of the study. Before beginning
the observation, data collectors will inform the patient that a survey is
being conducted during which the health care worker will be observed
giving an injection and ask for their permission.
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•

•

•

Supervisors are interviewed about documentation and logistical issues
related to injection equipment. These questions are not sensitive or
potentially stigmatizing, and the risk to their position is minimal. Data
collectors will not collect the names or other information to identify the
supervisor being interviewed.
Waste handlers are asked about waste handling practices, training,
protective equipment, etc. This activity is similar to supervisory visits and
the risk to their positions is minimal. Data collectors will not collect the
names or other information to identify the waste handler being
interviewed.
Feedback will be given to facility administrators about hazards needing
improvement and strengths without providing information that would allow
individuals to be identified. Hospital administrators will be informed prior to
data collection activities that feedback will not include any information that
could identify an individual (including department name).
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Table 4: Tentative Schedule for Data Collection
Day

Date

Activities

Comments

Day 1
Day 2
Day 3
Day 4
Day 5
Day 6
Day 7
Day 8
Day 9
Day 10
Day 11
Day 12
Day 13
Day 14
Day 15

4.7. Organization and Coordination of the Data Entry and Analysis
All collected data will belong to the MoH and MoH will share these data with the
CDC. Supervisors of the survey teams will check forms prior to leaving a facility
to make sure entries are legible and forms are complete. Nobody except
assessors, CAAP and CDC /CAR staff will have access to collected data.
Data will be captured on the assessment tools and entered into a data entry
program in Epi Info. The data collected will be codified prior to data entry,
especially in regards to open-ended questions. The data will be analyzed by
comparing facility-level indicators over time and when possible between districts
using Epi Info.
The survey questionnaires will be returned to the CDC office for data entry. The
data entry staff will be hired by the CDC/CAR. Access to the dataset will be
limited to the data entry staff and CDC epidemiologist who will oversee all
aspects of data coding, entry, cleaning and reporting. The data entry staff will
consist of 2 people, independently creating two databases which will be merged
to identify discrepancies. The data entry program will also have control checks to
ensure proper skips and logical values. Database will be protected by password.
This password will be available for data entry staff as well as CDC staff
responsible for data analysis. As disaster recovery measure data entered in the
computer will be backed up daily.
Hard copies of the observations and interviews will be stored in a locked cabinet.
The original data collection forms will be retained for three years following
completion of data entry, and then shredded Electronic database will be kept
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during three year period till analysis and report is prepared and presented to the
MoH.
Once that process is finished, the CDC specialist will send the data files and draft
report to CDC/Atlanta staff for review.
4.8. Analysis Plan
The analysis will be used to provide the types of expected results as described in
Section 3 of this protocol. The general analysis plan will be provided to the
person responsible for data analysis (See Appendix 5 under separate cover.)
This plan may be expanded as needed to accommodate additional questions
which are added to the questionnaires or areas of interest to partners in country.
The data will be analyzed to the extent possible:
• By type of facility (hospital vs. lower level)
• By hospital service department (medicine, pediatrics, ob-gyn, etc.)
• By type of injection (vaccination, curative, diagnostic)
• Per type of injection (IM, IV injection, IV infusion, phlebotomy)
For the evaluation component of the study in which we compare the likelihood of
observing unsafe injections pre- and post- intervention, we will use a frailty model
(a proportional hazards model with random effects terms). In this model
individuals are considered to have been observed over time, with time being the
injection number and a “death” is delivering the first unsafe injection5. In this
model sites are handled as the random effects term and the indicator for pre- or
post- intervention is consider a fixed effect. These models will be fit looking at
each type of injection separately.
4.9. Preparation of the Assessment Report
The report will be written based on the results of the database analysis. It will be
prepared by the CDC/CAR specialists, and will undergo technical review to
ensure the overall quality of the report. The report will follow the general outline
provided to the analyst and will cover the different topics mentioned in the
analysis plan. [See Appendix 5 for sample table of contents and Appendix 6
(under separate cover) for analysis plan.]
4.10. Dissemination of the Results of the Assessment
The results and the assessment will be presented as a report combined with
information from other countries at a regional workshop for all countries of CAR.
This workshop will include national decision makers, the survey team, directors
of large facilities where assessments were conducted and other national or
5

Injections are considered as deaths in this model in that once an unsafe injection is observed, the observer
may intervene and the health care worker referred for training. In this situation no further injections will be
observed.
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international agencies with an interest in the results. Results to be presented will
be shown as aggregated results by CAR region, district or by type of facility (such
as grouping all hospitals together, for example). Data from individual countries
will be presented only if there is preceding approval from the Ministry of Health of
each country to do so and countries will not be announced; each country will be
given a number -1, 2, 3 and 4. If one country objects, then all data will be
aggregated.
The final country-specific survey report will be shared with MOH. MOH will
decide the sharing mechanism with other counterparts. Results may also be
presented at conferences as lessons learned in the following areas (1) need for
changing the behavior of health care workers to ensure safe injection practices
through capacity building, behavior change and communications, and policy
interventions; (2) ensuring the availability of safe injection equipment and
supplies through procurement and logistics interventions; and (3) managing
health care waste safely and appropriately; (4) reduction/elimination of
unnecessary injections
4.11. Human Resources
The protocol was written by CDC/CAR and CDC/Atlanta staff, CV’s can be found
in Appendix 7.
Local consultants will be hired as a General Coordinator of the study, supervisors
for teams, data collectors for teams, and data entry clerks. The General
Coordinator, supervisors, and data collectors are usually doctors or nurses.
Consultant CVs will be made available and will be provided to the CAAP and
CDC/CAR offices and, through a collegial process guided by consensus,
individuals will be selected.
Data collectors will be trained in a classroom setting with an introduction to
Injection safety and waste management concepts. This training will include a
detailed review of the entire questionnaire including all instructions and skips.
Practice sessions will be held at a local hospital and lower level facility which are
not included in the sample. This visit provides an opportunity to standardize the
approach to data collection, to provide feedback on the performance of data
collectors, and to field test the questionnaires in the local context. In the first few
days of the actual data collection, data collectors will receive close support from
technical advisors and hired supervisors to ensure good quality data and to help
address any issues that arise. Data collectors are to be supervised throughout
data collection by supervisors; they should be provided with contact information
to have immediate access to a supervisor as needed during data collection.
Table 4: Tentative Composition of the Data Collection Teams per country
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AREA

Team Composition

#
People

#
Teams

Total

General Coordinator
( consultant)

1

__

1

Supervisors

4

4

4

12

4-6

12

Field Guide (local)

1

TBD

1

Data entry consultants

2

__

2

Coordination
Supervision
Data Collection
- Inventory Management
- Observations of Waste
Management
- Observations of Injection
Administration
- Interviews of providers,
supervisors, waste handlers and
patients

Data collectors

Support Activities
Data Entry

__

Epidemiologist CDC/CAR
Analysis of the Data

1

1
15

TOTAL

4.12. Material Resources
•

Vehicles
It will be necessary to mobilize a vehicle to transport each team of data
collectors and its supervisor to the districts and within each district. CAAP
is responsible for teams’ transportation.

•

Data Collection Tools - See under separate cover (Appendix 3).

•

Office Supplies
The data collectors will be given the following materials:
- Pencil, pen, eraser
- Folders for carrying completed forms and blank forms
- Memo pad for notes on problems to discuss with their supervisors
- Copies of the questionnaires
- Copies of consent forms
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•

Fuel
The fuel allocation necessary for travel of the assessment and
coordination teams from the capital to the districts and within the districts
will be reimbursed by CAAP.

•

Telecommunications Equipment
Always mobile telephone cards for communication between teams of data
collectors and supervisors and between the coordination team and the
supervisors. Telephone cards will be reimbursed by CAAP.
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